Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

Fig. 1

Flowchart of the selection process of the study population. In total, 94 patients were eligible for the study. Patients who met the exclusion criteria were not included, and only patients with previous failure of anti-TNF therapy were enrolled. The study population was stratified into groups according to treatment: vedolizumab or tofacitinib for UC patients and vedolizumab or ustekinumab for CD patients. UC, ulcerative colitis; CD, Crohn’s disease

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us